Jim Cramer is bullish on Freeport-McMoRan, Apple Hospitality REIT, and Abbott Laboratories.
Jim Cramer says that when the markets switch abruptly, investors should take the opportunity to go bargain hunting.
The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.
FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.
Investment firm Canaccord Genuity believes Kite Pharma is poised to take advantage of the positive results from Novartis' experimental gene therapy drug.